Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT02394912 | Terminated Results

• 1 other identifier: 140201
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF. The study will compare the method of Crux VCF deployment using the LUMIFI with Crux VCF System (IVUS guidance) with the historical results of the Crux VCF System (fluoroscopic guidance). The study will include enrollment into a roll in phase consisting of 2 study subjects per site prior to enrollment into the primary treatment phase for primary analyses. The purpose of the roll in phase is to assure compliance with site training on the use of the investigational device and protocol workflow.

Conditions

Pulmonary Embolism; Deep Vein Thrombosis

Keywords

vena cava filter

Outcome Measures

Primary Outcomes (1)

• Technical Success Rate

  All Subjects, Cohort A and Cohort B were included in the safety analysis. The primary endpoint of effectiveness, defined as technical success included only subjects within Cohort B. Technical success of filter placement is defined as the primary deployment of the filter such that the investigator judges the location to be suitable to provide sufficient mechanical protection against pulmonary embolism. Due to early stoppage of the study, enrollment of 100 subjects required to test the null hypothesis and evaluate the Primary Endpoint of Technical Success was not achieved. Therefore, a formal analysis of Technical Success was not performed.

  Day 1

Study Arms (1)

Single-arm

EXPERIMENTAL

Device: vena cava filter implantation (LUMIFI with Crux VCF System)

Interventions

vena cava filter implantation (LUMIFI with Crux VCF System) DEVICE

Single-arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient is \>18 years of age.
• Patient or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent
• Patient has appropriate femoral vein access
• Patient at risk for PE and meets at least one of the following sets of conditions:
• a. Documented DVT or PE and: i. Inability to anticoagulate the patient due to risk of bleeding such as recent surgery, trauma, intracranial bleed, GI bleed, OR ii. Progression/recurrence of DVT or PE on therapeutic anticoagulation, OR iii. Inability to anticoagulate due to high risk of tumor bleeding, OR iv. Patient unable to safely comply with anticoagulation, OR v. Patient that needs interruption of therapeutic anticoagulation such as at the time of an operation or other procedure.
• b. Patient that is high risk for DVT or PE and cannot be safely anticoagulated such as severe multi-trauma patient or patient having procedure with high risk for thromboembolism such as bariatric surgery.
• c. Patients with DVT at high risk for PE and free floating iliac or caval thrombosis d. Patients with compromised cardiopulmonary reserve from existing PE with right heart failure/strain who could not tolerate any further insult from new PE

You may not qualify if:

• Patient has any one of the following conditions:
• Thrombus in the iliac veins or the IVC that precludes access to appropriate placement of the Crux Filter
• Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC
• Known duplicated or left-sided IVC
• Known IVC transverse diameter at target lower renal ostia \> 28mm or \< 17mm
• Known extrinsic compression from abdominal or pelvic mass
• Known tumor thrombus involving the central venous system
• Uncontrolled sepsis, infection or persistent bacteremia
• Patient is at risk for septic pulmonary embolism
• Patient has an existing implanted filter in the IVC or superior vena cava (SVC) or underwent filter retrieval in previous 60 days.
• Patient has uncontrollable or active coagulopathy or known uncorrectable bleeding diathesis
• Patient has a condition that inhibits radiographic visualization of the IVC for post-deployment assessment
• Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol (nickel-titanium)
• Patients unwilling or unable to comply with the protocol
• Patients with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated

Sponsors & Collaborators

• Volcano Corporation: lead

Study Sites (2)

Surgical Care Associates

Louisville, Kentucky, 40207, United States

Location

Vascular Access Solutions

Orangeburg, South Carolina, 29118, United States

Location

MeSH Terms

Conditions

Pulmonary Embolism; Venous Thrombosis

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Embolism; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Thrombosis

Results Point of Contact

• Title: VP Clinical Trials
• Organization: Volcano

jonathan.batiller@philips.com

858-720-8731

Study Officials

• Donald Jacobs, MD

  St. Louis University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 5, 2015
• First Posted: March 20, 2015
• Study Start: June 1, 2015
• Primary Completion: November 9, 2016
• Study Completion: November 9, 2016
• Last Updated: July 30, 2019
• Results First Posted: June 11, 2018

Record last verified: 2019-07

Locations

US (2)